Aniruddha Hazra is an Infectious Disease physician affiliated with Howard Brown Health Center. OpenAlex indexes 119 publications with 1,789 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
888-824-0200Registry record last updated 24 Oct 2022.
Clinical trials
- A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population
Sponsor: University of Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year202520 payments
- Abbott LaboratoriesProgram year20252 payments
- Gilead Sciences, Inc.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
84.3%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor30%Cabenuva43%Dovato34%Tivicay22%Part D<11 patientsProtease Inhibitor18.4%Symtuza56%Prezcobix44%Part D<11 patients+ 4 more classes in this area
Cardiovascular
10.3%Statin5.4%Atorvastatin Calcium100%Part D<11 patientsCalcium channel blocker4.9%Amlodipine Besylate100%Part D<11 patientsRespiratory
5.4%beta2-Adrenergic Agonist5.4%Albuterol Sulfate Hfa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic
Open Forum Infectious Diseases
2025 - Resurgence of syphilis among blood donors in a single institute in Eastern India: a looming threat to public health and transfusion services
The Lancet Regional Health - Southeast Asia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”